同步放疗联合奈达铂、紫杉醇治疗宫颈癌的临床效果评价

发布时间：2018-01-26 14:21

本文关键词： 宫颈癌放疗化疗奈达铂紫杉醇疗效　出处：《中华肿瘤防治杂志》2016年S2期 　论文类型：期刊论文

【摘要】：目的研究观察同步放疗联合奈达铂、紫杉醇在宫颈癌治疗中的临床效果。方法选择2012-02-2015-02我院收治的48例宫颈癌患,按治疗方法分为联合组和对照组。联合组采用同步放疗联合奈达铂+紫杉醇治疗,对照组采用单纯同步放疗进行治疗,对比两组患者治疗效果。结果联合组肿瘤缓解总有效率为87.5%,对照组58.33%,数据比较差异均具有统计学意义,P0.05;联合组各项不良反应发生率高于对照组,数据比较差异不具有统计学意义,P0.05;随访12个月,联合组总生存率83.3%、无远处转移生存率75.0%、无局部复发率79.2%均明显高于对照组54.2%、45.8%、50%,数据比较差异具有统计学意义,P0.05。结论同步放疗联合奈达铂+紫杉醇治疗可对肿瘤达到有效缓解,改善肿瘤分期,提高患者生存率,具有较高安全性,治疗效果显著。
[Abstract]:Objective to observe the clinical effect of simultaneous radiotherapy combined with nedatin and paclitaxel in the treatment of cervical cancer. Methods 48 cases of cervical cancer were treated in our hospital from 2012-02-2015-02. According to the treatment method, the combined group was divided into the combined group and the control group. The combined group was treated with simultaneous radiotherapy combined with nedatin paclitaxel, while the control group was treated with simple simultaneous radiotherapy. Results the total effective rate of tumor remission was 87.5 in the combined group and 58.33 in the control group. The incidence of adverse reactions in the combined group was higher than that in the control group, and there was no significant difference in the data between the two groups (P 0.05). After 12 months follow-up, the overall survival rate of the combined group was 83.3%, the survival rate without distant metastasis was 75.0%, and the non-local recurrence rate of 79.2% was significantly higher than that of the control group (54.25.8%). Conclusion simultaneous radiotherapy combined with neidplatin paclitaxel can improve the tumor stage and survival rate. It has high safety and remarkable therapeutic effect.
【作者单位】：浙江省中医院妇科;
【分类号】：R737.33
【正文快照】： 中华肿瘤防治杂志,2016,23(S2):267-268宫颈癌是妇科常见恶性肿瘤,在女性恶性肿瘤发病率中位居第二,其病情发展迅速,具有较高的死亡率[1]。其发病因素包括病毒感染、分娩、性行为、营养不良、卫生习惯差等,其中持续高危型HPV病毒感染为主要因素,约占致病原因的90%,原位宫颈癌

【参考文献】